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It is unknown whether first-generation electronic cigarettes reduce smoking urges and withdrawal symptoms following a 24 h
deprivation period. This study tested whether a first-generation electronic cigarette reduces smoking urges and withdrawal
symptoms in cigarette smokers. Following 24 h of tobacco deprivation, using a within-subjects design, eight nontreatment seeking
tobacco cigarette smokers (3 females) administered 10 puffs from a conventional cigarette or a first-generation electronic cigarette
containing liquid with 0, 8 or 16mg/ml nicotine. Conventional cigarettes ameliorated smoking urges and electronic cigarettes
did not, regardless of nicotine concentration. First-generation electronic cigarettes may not effectively substitute for conventional
cigarettes in reducing smoking urges, regardless of nicotine concentration.
1. Introduction
Electronic cigarettes (ECs) are battery-powered devices that
use a heated coil to aerosolize liquids typically containing
nicotine. At least three separable categories of ECs have
been recognized: first-, second-, and third-generation. First-
generation ECs have relatively low-capacity batteries, typi-
cally nonrefillable liquid cartridges, and few (if any) variable
settings, operate at lower wattages, and are activated when
the user inhales. Second-generation devices typically have
larger rechargeable batteries, refillable liquid tanks, and some
adjustable parameters (e.g., variable voltage) that allow the
users to tailor the function of the device and are activated by
pressing a button as a user inhales. Third-generation devices
are similar to second-generation devices with the addition
of a greater number of user-customizable parameters (e.g.,
voltage or wattage) and configurations (e.g., different types of
tanks or batteries). Recent survey data suggest that tobacco
cigarette smokers often begin using first-generation ECs and
then later transition to 2nd- or 3rd-generation devices [1].
Tobacco smokers initiate EC use with a first-generation
device because they more closely resemble tobacco cigarettes
compared to 2nd- and 3rd-generation devices [1]. It is also
possible that smokers are attracted to them because of their
lower cost andwider availability compared to later generation
devices. Since many begin EC use with a first-generation EC,
initial experiences with first-generation ECs likely influence
the probability to continue use of ECs.
Previous studies suggest that first-generation ECs con-
taining liquids with 16–18mg/ml nicotine concentrations,
and to a lesser extent a 0mg/ml nicotine concentration, ame-
liorate some smoking urges and withdrawal symptoms [2, 3].
Yet, those studies have used tobacco deprivation periods of
12 h or less prior to administration of an EC [2–5]. Further,
none of the aforementioned studies collected baseline mea-
sures of smoking urges and withdrawal symptoms prior to
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tobacco deprivation and are unable to differentiate symptom
alleviation from other subjective effects following EC self-
administration. Thus, there has not yet been a rigorous
examination of alleviation of smoking urges and withdrawal
symptoms by first-generation ECs following 24 h tobacco
deprivation. The present study compared the effects of a
prototypical first-generation EC using three nicotine con-
centrations (0, 8, and 16mg/ml) on smoking urges and
withdrawal symptoms following 24 h of smoking deprivation;
a conventional tobacco cigarette (CC) was also tested as a
positive control and comparator for the EC conditions.
2. Materials and Methods
2.1. Participants. Participants were recruited from the com-
munity using online advertisements. Respondents completed
medical and psychological screening questionnaires, a one-
year timeline follow-back for CC use, the Fagerstrom Test for
Nicotine Dependence, and a questionnaire assessing lifetime
quantity and frequency of EC use. Inclusion criteria were
smoking an average of 10 or more nonmenthol tobacco
cigarettes per day for at least one year, breath carbon monox-
ide (CO) levels of 10 ppm or higher during screening, and not
being a regular EC user (defined as daily use of an EC for the
past seven days). Individuals were excluded if they expressed
interest or engagement in smoking cessation treatment. The
University of Kentucky Medical Institutional Review Board
approved this study.
A total of 9 individuals (3 females), between 22 and 47
years of age,met eligibility criteria and started the study. Eight
completed the study; one female participant failed tomeet the
tobacco deprivation breath CO criterion needed to begin the
study on two occasions and then was lost to follow-up. All
participants identified their race as Caucasian.
2.2. Design. A placebo-controlled, double-blind, random-
ized, within-subject design was used to examine the behav-
ioral effects of controlled puffs from a CC (participant’s own
brand) and EC producing aerosol from commercial solutions
containing 0, 8, or 16mg/ml of nicotine following 24 h of
smoking deprivation.
2.3. Schedule. The study consisted of one 4 h practice session
followed by four two-session test blocks; a minimum of 48 h
separated each test block. Based on convenience, participants
chose session start times that remained constant throughout
their participation in the study.
The practice session was designed to familiarize partici-
pants with how to use the EC [4]. Following 24 h of tobacco
deprivation, participants administered six puffing bouts from
an EC with 16mg/ml nicotine concentration, with each bout
consisting of 10 puffs.The six bouts were separated by 30min.
Test blocks were designed to measure the effects of
CC and EC use following 24 h of smoking deprivation.
Each test block consisted of a “baseline” session, which was
not associated with any restrictions on tobacco smoking,
directly followed by 24 h of tobacco deprivation, and then
a “deprivation” session. During each session, a behavioral
assessment was completed before and after administration of
a puff bout consisting of 10 two-second puffs, each separated
by 30 seconds. During the “baseline” session, puff bouts were
always administered from a CC. A puff bout from either
an EC with one of three nicotine concentrations (0, 8, and
16mg/ml) or a CC was administered in random order during
the “deprivation” sessions. The paced puffing procedure was
utilized for administering puff bouts in order to maintain
standardized puffing topographies across all test conditions,
and adherence to the paced puffing procedure was verified by
staff members using camera images of participants smoking,
and inhalation data displays from a volumetric transducer.
During the four test blocks the effects of EC, with one of three
nicotine concentrations (0, 8, and 16mg/ml), or a CC, were
tested in a randomized order.
Compliance with the 24 h tobacco deprivation conditions
prior to the practice session and each of the four “deprivation”
sessions during test blockswas verified using breathCO crite-
ria of ≤6 ppm or 10% of predeprivation breath CO, whichever
was greater. Sessions were rescheduled if participants failed to
meet the breath CO criteria. On two occasions this occurred
within test blocks; participants restarted the two-day block
(i.e., repeated the “baseline” session) on each occasion.
2.4. Assessments. To assess smoking withdrawal symptoms
the Minnesota Nicotine Withdrawal Scale (MNWS) [6] was
used. The Questionnaire of Smoking Urges-Brief (QSU-B)
[7] was used to assess smoking urges, and the Visual Analog
Scale-Smoking Effects (VAS-SE) [8] andVisual Analog Scale-
Postsmoking (VAS-PS) assessed smoking or EC use effects.
Cognitive tasks included the Digit Symbol Substitution Task
(DSST) [9] and the Rapid Information Processing Task (RIP)
[10]. Heart rate and blood pressure were also recorded.
2.5. Drug. A Blu cartomizer with “Classic Tobacco” liquid
flavoring (Lorillard Technologies, Inc., Greensboro, NC), a
first-generation EC widely available throughout the United
States, served as the EC (webpage for this device archived at
http://www.webcitation.org/6nuZa31ga). Cartomizers were
all purchased simultaneously at the beginning of the study in
order tominimize possible variations in batches. Cartomizers
offered by the manufacturer with the labels “no nicotine”
(0mg/ml), “low nicotine” (6–8mg/ml), and “high nicotine”
(14–16mg/ml) were used to experimentally manipulate nico-
tine concentrations. Cartomizer labels were covered from
study participants and investigators working on this study
to maintain the double-blinded design. Nonmenthol com-
mercially available own brand cigarettes (i.e., participants
preferred brand) were supplied for the CC conditions.
2.6. Data Analysis. To identify tobacco deprivation effects
on withdrawal symptoms and smoking urges, presmoking
assessments during “baseline” and “deprivation” sessions
were compared. To determine if EC or CC use altered
smoking urges and withdrawal symptoms, reports of with-
drawal symptoms and smoking urgeswere compared prior to,
and following, EC or CC administration during deprivation
sessions. Separate mixed models were used to test for effects
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Figure 1: Self-report of “I have a desire for a cigarette right now.” Subjective ratings of “I have a desire for a cigarette right now” on a 100-
point Visual Analog Scale. A significant decrease was observed following baseline session smoking and a significant increase was observed
following 24 h tobacco deprivation. Ratings prior to CC (own brand) or EC use during deprivation sessions were also significantly higher than
presmoking ratings during baseline sessions. Following cigarette administration during deprivation sessions, CC engendered significantly
lower ratings compared to EC dispensing aerosol from 0, 8, or 16mg/ml nicotine concentrations. ∗∗∗p < .001.
between each time point, with dose condition as a variable
only for models examining change in smoking urges and
withdrawal symptoms before and after CC or EC use during
deprivation sessions. When significant effects of dose con-
dition were found, post hoc analyses were conducted using
t-tests to examine differences between least-square means
of each dose condition. Hochberg’s step-up procedure [11]
was used to control error rates for each family of pairwise
comparisons. Mixed models were fit using PROC Mixed in
the SAS statistical software package, version 9.3 (SAS Institute
Inc., Cary, NC).
3. Results and Discussion
3.1. Results. Six of eight participants had previously used an
EC, with an average of 27 days (SE = 13) of lifetime use, and
last use occurring an average of 256 days (SE = 142) prior to
screening. Participants reported smoking an average of 20 (SE
= 3.3) cigarettes per day and scored an average of 5.6 (SE = .8)
on the Fagerstrom Test for Nicotine Dependence. Minimal
alcohol (M = .8, SE = .3 days/week) and marijuana (M = .9,
SE = .6 occasions/month) use was reported. Breath CO levels
decreased from an average of 29.0 ppm (SE = 5.9) prior to
smoking on “baseline” sessions to an average of 5.5 ppm (SE
= .4) prior to smoking during “deprivation” sessions.
Statistically significant (ps < .05) withdrawal symptoms
were observed on seven of thirteen MNWS items and heart
rate (“baseline versus 24-Dep” column in Table 1).There were
no significant withdrawal effects on cognitive tasks (DSST
and RIP) or VAS measures of smoking effects.
Mixed models indicated a significant effect of drug on
“desire or craving to smoke” on the MNWS (𝐹[3, 21] = 3.29,
p = .041), six of nine measures on the QSU-B (ps < .05), and
heart rate (𝐹[3, 21]=3.45, p= .035) followingCCorECuse on
deprivation sessions. Following CC use, post hoc estimates of
least-square means indicated a significant decrease of “desire
or craving to smoke” on the MNWS, six of nine items on
the QSU-B (e.g., “I have a desire for a cigarette right now,”
“I am going to smoke as soon as possible”), and a significant
increase in heart rate (least-square means of these changes
shown in Table 1). A prototypical example of the pattern of
effects on subjectivemeasures is indicated on theQSU-B item
“I have a desire for a cigarette right now,” shown in Figure 1.
No significant reductions in smoking urges were indicated
following use of the EC at any nicotine concentration.
The mixed model for change in total trials on the DSST
frombefore to after CC or EC use during deprivation sessions
indicated a significant effect of drug (𝐹[3, 21] = 3.18, p =
.045). Post hoc estimates of least-square means indicated
significant increases in total trials on the DSST following CC
and 8mg/ml EC (Table 1). The mixed model for rating of
“Lightheaded” on the VAS-SE from before to after CC or EC
use during deprivation sessions indicated a significant effect
of drug (𝐹[3, 21] = 8.90, p < .001). Post hoc estimates of
least-square means indicated a significant increase in rating
of “Lightheaded” on the VAS-SE following CC, but not ECs
(Table 1). Neither of these measures was altered by tobacco
deprivation (Table 1). The VAS-PS was only administered
following EC or CC use and, compared to CC, significantly
lower ratings of “did you like the effects?” were observed
following use of EC at all nicotine doses (𝑡[21] = 2.89 to 3.56,
p < .001) and “did you enjoy the cigarette?” (𝑡[21] = 3.40, p =
.003) and “do you feel stimulated?” (𝑡[21] = 3.50, p = .002)
following the 0mg/ml EC condition; significantly higher
ratings of “do you want to smoke again?” were observed
following use of EC at all doses (𝑡[21] = 4.19 to 5.55, p < .001).
3.2. Discussion. This study examined the subjective andphys-
iological effects of a commercially available first-generation
EC delivering aerosol from experimentally manipulated
nicotine concentrations compared to preferred brand CCs
among regular tobacco smokers following 24 h of tobacco
deprivation. Reports of withdrawal symptoms and increases
in smoking urges were observed on the MNWS, and QSU-
B, and on heart rate following 24 h of tobacco deprivation.
Smoking CCs after 24 h of tobacco deprivation ameliorated
the increase in smoking urges and physiological withdrawal
symptoms (i.e., heart rate), while no attenuation of these
effects followed use of ECs, regardless of nicotine concen-
tration. An isolated effect of 8mg/ml EC was observed on
4 Journal of Addiction
Table 1: Least-square mean changes in subjective, cognitive, and physiological effects by session and condition.
Variable Baseline versus24-Dep.
Conventional
cigarette
Electronic cigarette nicotine concentrations
0mg/ml 8mg/ml 16mg/ml
Rapid Information Processing Task
Digit rate 4.59 5.72 −2.90 2.69 5.68
Reaction time on correct trials −6.94 0.13 20.13 −11.00 −6.88
Proportion correct 0.04 0.05 0.02 0.00 0.04
Commission errors 0.00 0.00 0.00 0.00 0.00
Digit Symbol Substitution Task
Total trials completed −1.34 4.13∗∗ −1.25 4.50∗∗ 2.38
Percentage trials correct 0.00 0.01 0.01 0.04 0.01
Visual Analog Scale-Smoking Effects
Confused −0.09 2.38 0.88 0.25 1.88
Dizzy 0.41 11.13 −1.88 0.75 1.13
Headache 4.63 −2.75 −3.25 −1.50 −1.25
Heart pounding 0.22 1.45 0.38 0.00 1.01
Lightheaded 0.03 18.88∗∗∗ 0.75 2.75 0.25
Nausea −0.47 0.38 0.00 0.00 0.00
Nervous 1.09 1.75 0.25 −1.63 −2.50
Salivation −0.03 4.50 −1.25 1.00 5.50
Sweaty 0.03 0.00 −0.13 0.00 0.00
Weak 1.78 −2.38 −1.50 −1.00 0.00
Minnesota Nicotine Withdrawal
Scale
Angry, irritable, or frustrated 0.72∗∗∗ −0.63 0.00 −0.25 −0.63
Anxious or nervous 0.13 0.00 0.00 −0.13 0.00
Depressed mood or sad 0.19∗ −0.13 0.00 −0.13 −0.13
Desire or craving to smoke 1.09∗∗∗ −2.25∗∗∗ −0.75 −0.63 −0.88
Difficulty concentrating 0.50∗ −0.38 −0.38 −0.38 −0.13
Increased appetite, hungry, or
weight gain 0.28
∗
−0.50 −0.25 0.00 −0.13
Restless 0.41∗ −0.50 0.00 0.00 −0.25
Impatient 0.69∗∗ −0.88 −0.13 −0.25 −0.25
Constipated 0.06 0.00 0.00 0.00 0.00
Dizziness 0.00 0.38 0.00 0.13 0.13
Coughing −0.03 0.38 0.00 0.25 0.50
Nauseous −0.03 0.00 0.00 0.00 0.00
Sore throat 0.00 0.25 0.13 0.25 0.38
Total score 4.00∗∗∗ −4.25 −1.38 −1.13 −1.38
Questionnaire of Smoking
Urges-Brief
I have a desire for a cigarette right
now 22.78
∗∗∗
−51.25∗∗∗ −6.50 −8.63 −10.00
Nothing would be better than
smoking a cigarette right now 19.09
∗∗
−31.38 −12.25 −4.50 −14.13
If it were possible I would
probably smoke now 25.31
∗∗∗
−64.00∗∗∗ −13.50 −15.13 −13.38
I could control things better right
now if I could smoke 9.38
∗
−19.38 −6.63 −13.38 −0.50
All I want right now is a cigarette 19.63∗∗ −33.86∗∗∗ −6.25 −14.88 −10.25
I have an urge for a cigarette 25.88∗∗∗ −52.25∗∗∗ −7.75 −14.38 −15.50
A cigarette would taste good now 20.38∗∗∗ −44.00∗∗∗ −8.63 −14.88 −12.38
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Table 1: Continued.
Variable Baseline versus24-Dep.
Conventional
cigarette
Electronic cigarette nicotine concentrations
0mg/ml 8mg/ml 16mg/ml
I would do almost anything for a
cigarette now 14.94
∗∗
−27.13 −1.13 −8.63 −6.38
Smoking would make me less
depressed 8.84 −5.75 0.75 −2.00 −2.50
I am going to smoke as soon as
possible 24.84
∗∗
−47.50∗∗∗ −6.00 −17.50 −14.8
Heart rate and blood pressure
Heart rate −8.59∗∗ 16.38∗∗∗ 3.50 4.50 0.63
Mean arterial pressure −3.61 6.04 1.71 2.04 0.96
All values are least-square means estimates from mixed models. Baseline versus 24-Dep = mean change between presmoking during baseline sessions and
prior to OB or EC use during deprivation sessions. Own brand and electronic cigarette nicotine concentrations columns represent mean changes between pre-
and postuse of OB or EC during deprivation sessions. ∗𝑝 ≤ .05, ∗∗𝑝 ≤ .01, and ∗∗∗𝑝 ≤ .001.
DSST trial rate; since DSST performance was not altered by
tobacco deprivation, this would not be considered a tobacco
withdrawal alleviation effect.
Self-reported smoking urges and withdrawal effects were
consistent with previous research [7, 8], and reports of
“desire or craving to smoke” on the MNWS and six QSU-
B items (e.g., “I have a desire for a cigarette right now,”
Figure 1) measured during deprivation sessions significantly
decreased following smoking CCs but not ECs, suggesting
that first-generation ECs may be less effective than CCs in
managing self-reported smoking urges. This is consistent
with previous studies comparing CCs to ECs delivering
aerosol from a single nicotine concentration [2, 3, 12]. Unlike
previous studies [2–5], however, the first-generation EC
tested here failed to attenuate any smoking urges. There
are several possible explanations for the failure of a first-
generation EC to attenuate smoking urges following 24 h
tobacco deprivation in this study. First, previous studies did
not differentiate whether or not EC effects were associated
with the alleviation of verified tobacco deprivation effects
(i.e., symptoms measured pre- and postsmoking depriva-
tion). The current study, however, used a baseline session
prior to testing each EC and CC condition in order to focus
only on verified tobacco deprivation effects. This difference
likely made the current study relatively more conservative
in terms of which variables were considered “withdrawal
symptoms.” Second, the 24 h deprivation period used in
the current study might have engendered larger deprivation
effects that were insensitive to use of the first-generation
ECs. Third, two of the aforementioned studies used ad-
lib puffing periods from ECs with 16 or 18mg/ml nicotine
concentrations [2, 5], suggesting that allowing the user to
control the timing and number of puffs from an EC might
more effectively ameliorate withdrawal symptoms. Fourth,
the aforementioned studies did not use Blu ECs, and these
devicesmight not be as effective at delivering nicotine as first-
generation ECs used in other studies. It is also worth noting
that newer ECs that are more powerful (greater wattage)
or contain higher nicotine concentrations might be more
effective at delivering nicotine and reducing tobacco urges
and withdrawal symptoms compared to the device used in
this study. Fifth, although previous research has indicated
that the nicotine concentration in at least one commercially
obtained Blu EC cartomizer was accurate [13], the reliability
of the packaging label is not known, nor is the concentration
of nicotine delivered in aerosol. Sixth, six of eight participants
in this study had reported having discontinued use of an
EC, with minimal prior EC use (m = 27 days since last use).
The fact that these six participants had discontinued use of
an EC and that two participants had never attempted to use
an EC previously may indicate that the sample used in this
study is biased towards individuals who are less likely to
respond to ECs. Lastly, although procedures demonstrated to
be effective in training participants to extract nicotine from
first-generation devices were used here [4], nicotine delivery
was not assessed biologically and the absence of effect on
tobacco withdrawal symptoms might be due to ineffective
nicotine delivery. In conclusion, this type of EC may not be
effective at reducing tobacco urges when used under similar
conditions as the current study.
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